Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.
Marchesi F, Pimpinelli F, Sperandio E, Papa E, Falcucci P, Pontone M, di Martino S, de Latouliere L, Orlandi G, Morrone A, Ciliberto G, Mengarelli A; I.F.O.-COVID-19-Team. Marchesi F, et al. Among authors: falcucci p. Br J Haematol. 2022 Jan;196(2):362-367. doi: 10.1111/bjh.17821. Epub 2021 Sep 6. Br J Haematol. 2022. PMID: 34490627 Free PMC article. No abstract available.
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.
Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, Pontone M, Di Martino S, Laquintana V, La Malfa A, Di Domenico EG, Di Bella O, Falzone G, Ensoli F, Vujovic B, Morrone A, Ciliberto G, Mengarelli A. Pimpinelli F, et al. Among authors: falcucci p. J Hematol Oncol. 2021 May 17;14(1):81. doi: 10.1186/s13045-021-01090-6. J Hematol Oncol. 2021. PMID: 34001183 Free PMC article. Clinical Trial.
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia.
Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, Spadea A, Pontone M, Di Martino S, Laquintana V, La Malfa A, Di Domenico EG, Di Bella O, Falzone G, Ensoli F, Vujovic B, Morrone A, Ciliberto G, Mengarelli A. Pimpinelli F, et al. Among authors: falcucci p. J Hematol Oncol. 2021 Jul 29;14(1):119. doi: 10.1186/s13045-021-01130-1. J Hematol Oncol. 2021. PMID: 34325728 Free PMC article.
Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas.
Marchesi F, Pimpinelli F, Giannarelli D, Ronchetti L, Papa E, Falcucci P, Pontone M, Di Domenico EG, di Martino S, Laquintana V, Mandoj C, Conti L, Cordone I, La Malfa A, Viggiani C, Renzi D, Palombi F, Romano A, Pisani F, Gumenyuk S, Di Bella O, Vujovic B, Morrone A, Ciliberto G, Ensoli F, Mengarelli A. Marchesi F, et al. Among authors: falcucci p. Leukemia. 2022 Feb;36(2):588-590. doi: 10.1038/s41375-021-01418-8. Epub 2021 Sep 20. Leukemia. 2022. PMID: 34545184 Free PMC article. No abstract available.
Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience.
Autore F, Stirparo L, Innocenti I, Papa E, Marchesi F, Togni C, Mariani S, Torrieri L, Salvatori M, Fazio F, Metafuni E, Giammarco S, Sora F, Falcucci P, Ferrari A, Trisolini SM, Capria S, Tafuri A, Chiusolo P, Sica S, Laurenti L. Autore F, et al. Among authors: falcucci p. Front Oncol. 2022 Dec 2;12:897937. doi: 10.3389/fonc.2022.897937. eCollection 2022. Front Oncol. 2022. PMID: 36531008 Free PMC article.
Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim.
Marchesi F, Terrenato I, Papa E, Tomassi M, Falcucci P, Gumenyuk S, Palombi F, Pisani F, Renzi D, Romano A, Spadea A, Regazzo G, Rizzo MG, De Rienzo M, Ripellino C, Sgromo S, Viggiani C, Ponte E, Kayal R, Cordone I, Foddai ML, Mengarelli A. Marchesi F, et al. Among authors: falcucci p. Ann Hematol. 2024 Mar;103(3):947-956. doi: 10.1007/s00277-023-05604-9. Epub 2024 Jan 8. Ann Hematol. 2024. PMID: 38189833 Free PMC article.
Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region.
Autore F, Innocenti I, Corrente F, Del Principe MI, Rosati S, Falcucci P, Fresa A, Conte E, Limongiello MA, Renzi D, De Padua L, Andriani A, Pisani F, Cimino G, Tafuri A, Montanaro M, Mauro FR, Del Poeta G, Laurenti L. Autore F, et al. Among authors: falcucci p. Front Oncol. 2020 Jun 10;10:848. doi: 10.3389/fonc.2020.00848. eCollection 2020. Front Oncol. 2020. PMID: 32587827 Free PMC article.
Acute megakaryoblastic leukemia: experience of GIMEMA trials.
Pagano L, Pulsoni A, Vignetti M, Mele L, Fianchi L, Petti MC, Mirto S, Falcucci P, Fazi P, Broccia G, Specchia G, Di Raimondo F, Pacilli L, Leoni P, Ladogana S, Gallo E, Venditti A, Avanzi G, Camera A, Liso V, Leone G, Mandelli F; GIMEMA. Pagano L, et al. Among authors: falcucci p. Leukemia. 2002 Sep;16(9):1622-6. doi: 10.1038/sj.leu.2402618. Leukemia. 2002. PMID: 12200673 Clinical Trial.
Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome.
Laurenti L, De Padua L, Tarnani M, Piccirillo N, Falcucci P, D'Arena G, Innocenti I, Marietti S, Efremov DG, Chiusolo P, Zini G, Sora' F, Sica S, Leone G. Laurenti L, et al. Among authors: falcucci p. Ann Hematol. 2011 Jan;90(1):59-65. doi: 10.1007/s00277-010-1025-y. Epub 2010 Jul 13. Ann Hematol. 2011. PMID: 20625902
24 results